Snapchat is courting pharma marketers with a new ad format designed to support the disclosure needs of branded prescription drug campaigns. Advertisers on Snapchat, a social media platform on which ...

As Alnylam’s Amvuttra sales disappointed, revenue from BridgeBio’s rival transthyretin amyloidosis (ATTR) drug Attruby came in above analysts’ expectations. | Despite their divergent second-quarter ...

WuXi AppTec has been caught in the crosshairs of ongoing scrutiny over China’s booming biotechnology industry since 2024, when the Biosecure Act, which aims to keep taxpayer dollars away from “foreign ...

Bristol Myers Squibb has laid out plans for a $2.3 billion manufacturing facility in Houston, set for completion in 2030. The plant will cover 600,000 square feet and employ nearly 500 people.

Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to ...

ITM’s application rested on data from the phase 3 Compete trial in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These malignancies arise in a specialized group of neurons ...

Abbott has enlisted telenovela star Gabriela Spanic to push the message that getting screened for colon cancer doesn’t have ...

Scholar Rock has shed Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a candidate for spinal muscular atrophy. The Cambridge, ...

Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to ...

Inizio’s Engage arm is widening its global medical information offerings with its new ‘Connected Insights’ platform. The new expansion merges regional expertise in the Asia-Pacific market, enhanced ...

After coming up short in trials with two orexin type 2 receptor (OX2R) selective agonists, Takeda has scored with oveporexton ...

Novo’s Wegovy pill thesis continues to bear out in 2026, as the oral obesity med keeps impressive sales apace while sparing ...